Feb 20, 2012
The Vitamin D MS Progression Impact Clinical Trial, which is being funded solely by the Greater Delaware Valley Chapter, is expanding from eight to 12 sites. “People are quite excited by this trial,” explains Dr. Ellen Mowry, the lead investigator, from her office at John Hopkins University. In addition to Baltimore, there will be study sites in Philadelphia, St. Louis, Portland, New York and other major centers.
Mowry is conducting a randomized, double-blind clinical trial to determine whether high dose vitamin D added to standard therapy with glatiramer acetate (Copaxone ®, Teva Pharmaceutical Industries) reduces the frequency of MS relapses. In this trial, 172 people who have MS and are receiving standard glatiramer acetate treatment daily will be randomly assigned to take either 600 IU (the current recommended daily allowance) or 5000 IU of Vitamin D. Comparing these measures will show whether high-dose vitamin D supplements affects the course of MS in people who are taking a standard therapy.
Of the $1.3 million project, we have funded more than $800,000 through donations from people like you. Your research-restricted contribution will help us meet our goal of funding this historic project. To donate, click here or call Kristina McGraw at 215-271-1500.